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Abstract. The pharmacokinetic profile of recombinant
human erythropoietin (rHuEpo) was studied after a single
intravenous dose of 150 U/kg in ten patients with various
degrees of renal function: group I, creatinine clearance
>80ml/min, n = 2; group II, creatinine clearance
10-50 ml/min, w = 6; group III, creatinine clearance
<3ml/min (patients undergoing haemodialysis) n = 2.
Erythropoietin concentrations in serum and urine samples
obtained over 48 h were measured by RIA. rHuEpo was
cleared from circulation in an exponential fashion, the
half-life ranged from 6.5 to 12.7 h (mean 9.03 h) and was
not different between the groups. The apparent volume of
distribution varied from 0.041 to 0.099 I/kg (mean
0.070 I/kg) this corresponds to 1.5 times the plasma
volume and was unrelated to kidney function. Renal
clearance (groups I, II) accounted for less than 3% of
total body clearance, both parameters were unaffected by
decreasing renal function.
These results indicate that, in accordance with animal
data, the elimination of rHuEpo occurs mainly through
non-renal mechanisms.
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Introduction
Initial clinical experience with the use of recombinant
human erythropoietin (rHuEpo) for the treatment of the
anaemia of end-stage renal disease has been very encour-
aging, with correction of the anaemia in nearly all cases
and improvement of the well-being of patients on dialysis
[1,2]. However, relatively little is known about the
pharmacokinetic behaviour of erythropoietin; this is due
to a previous lack of sensitive and specific assay techniques
for the hormone. In recent preliminary pharmacokinetic
studies the plasma half-life of rHuEpo in humans ranged
between 4 h and 12 h [3-6]. The objective of the present
study was to determine the effect of decreasing renal func-
tion on the pharmacokinetic profile of the hormone after a
single intravenous dose.
Patients and Methods
Ten subjects aged 29-65 years, with a bodyweight
between 61 and 115 kg, were divided into three groups
according to their renal function: group I, creatinine
clearance > 80 ml/min per 1.73 m2, n = 2; group II, creati-
nine clearance 10-50 ml/min per 1.73 m2, n = 6; group III,
creatinine clearance < 3 ml/min per 1.73 m2 (patients
undergoing haemodialysis), n = 2.
The objectives and implications of the study were
explained and signed informed consent was obtained
from each subject, as specified in the declaration of
Helsinki (Tokyo revision 1975). Table I demonstrates
patient characteristics. Six of the eight patients with
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Table 1. Patient demographic data
Patient
1
2
3
4
5
6
7
8
9
10
Sex
m
m
m
m
m
w
m
m
w
m
Underlying
disease
Chronic bronchitis
Vasovagal syncope
Chronic glomerulonephritis
Chronic glomerulonephritis
Chronic glomerulonephritis
Chronic glomerulonephritis
Chronic pyelonephritis
Chronic glomerulonephritis
Chronic pyelonephritis
Chronic glomerulonephritis
Creatinine
clearance
(ml/min/ 1.73 m2)
102
100
50
50
20
20
7.9
7.9
0
0
Haematocrit
(Vol %)
40
44
48
42
33
—
40
30
20
24
Erythropoietin
(mU/ml)
19
22
13
13
—
13
17
17
16
IS
chronic renal failure had chronic glomerulonephritis,
four of the ten patients suffered from anaemia with a
haematocrit less than 33%. In all subjects the serum con-
centrations of erythropoietin were in the normal range
(10-25 mU/ml). Especially in the two dialysis patients, the
serum hormone concentrations were inappropriately low
for the degree of anaemia.
The recombinant human erythropoietin was dissolved
in 2 ml of sterile distilled water and subsequently adminis-
tered as a single intravenous bolus injection to each
patient in a dosage ranging from 130 to 152 U/kg body-
weight. Venous blood samples (1 ml) for assay of erythro-
poietin were obtained by venepuncture immediately
before and 0.25, 0.5, 0.75, 1,2,3,4,5,6,8, 10,12, 18,24,
36, 40 and 48 h after administration. Blood specimens
were collected in vacutainers and centrifuged, and the
serum separated and frozen at — 20°C until analysis.
Urine was collected during the 48-h period in all subjects
except the two dialysis patients. The total volume of urine
voided during the collection period was measured and
mixed thoroughly. A 10-ml aliquot from each urine
collection was removed and stored frozen at — 20°C until
analysis.
Erythropoietin was estimated in serum and urine
samples as described previously [7], using a radioimmuno-
assay based on rHuEpo as tracer and immunogen.
The lower detection limit of the assay is 5 mU Epo/ml,
the interassay coefficient of variation is 6.7% (51
estimations of a sample containing 44.2 + 3.0 mU Epo/ml;
mean ± SD). To eliminate differences in dosages the serum
concentrations were corrected to a dosage of 150 U/kg
bodyweight. Model-independent pharmacokinetic par-
ameters, including time-independent peak values were
obtained directly from the data. The further parameters
were calculated according to standard pharmacokinetic
equations [8], for example the areas under the concen-
tration-time curve (AUC) were calculated by the
trapezoidal rule and the elimination rate constant k was
obtained from the slope of the approximately log-linear
part of the concentration-time curve by linear regression.
The data were best fitted by a two-compartment open
model. Group data were expressed as x + SEM.
4 8
Fig. 1. Serum concentration-time profile after a single intravenous appli-
cation of rHuEpo in a dosage of 150 U/kg body weight to ten patients
with various degress of renal function. (Upper panel: semilogarithmic
plot of serum concentration.)
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Table 2. Pharmacokinetic parameters of recombinant human erythropoietin (rHuEpo) in patients with various degrees of
renal function
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Patient
Group
Creatinine clearance
> 80 ml/min
Mean
SEM
II
Creatinine clearance
10-50 ml/min
Mean
SEM
III
Creatinine clearance
< 3 ml/min
Mean
SEM
Total mean
SEM
A U C 0 . 4 8
(mU/h/ml)
20 539.4
290.3
29497.8
2 219.7
31 375.9
6 550.7
28081.7
2058.2
1,29
(h)
8.52
1.02
8.76
0.89
10.37
2.35
9.03
0.68
v,
(I/kg)
0.088
0.011
0.065
0.008
0.069
0.0005
0.070
0.006
».*
(h)
2.36
0.84
1.94
0.59
1.46
0.16
1.93
0.36
a
(ml/min/kg)
0.1197
0.0005
0.0855
0.0069
0.0803
0.0190
0.0913
0.0071
(ml/min/kg)
0.0011
0.0002
0.0019
0.0052
—
—
0.0017
0.0002
Cljin
ofCl
0.92
0.17
2.24
0.32
—
—
1.86
0.33
AUC = area under serum concentration-time curve
t, ,„ = terminal half-life
t, j , = half-life of the distribution phase
Vz=apparent volume of distribution
Cl = total body clearance
CL = renal clearance
Results
Figure 1 demonstrates the 48-h profiles of average serum
erythropoietin concentrations for all ten patients after the
single intravenous administration of the hormone. The
time-independent peak values ranged between 1.781 and
3.647 mU/ml (mean 2910.5 mU/ml) and did not differ
between groups. Recombinant human erythropoietin was
cleared from circulation in a complex manner. Using the
semilogarithmic plot of serum concentration (upper panel
of Fig. 1), a biexponential decay curve was obtained.
After an initial faster decline corresponding to the distri-
bution phase, a slower decrease of serum erythropoietin
concentration can be observed, which represents the
elimination of the hormone. When the early phase of the
disappearance curve (reflecting mainly distribution and
elimination effects) is excluded, the apparent serum half-
life of rHuEpo averaged 9.03 h (range 6.5-12.7 h) and was
unrelated to renal function (Table 2.)
Figure 2 shows the comparative time courses of mean
• serum concentrations of erythropoietin after a bolus
injection of 150 U/kg bodyweight in the three patient
groups. The areas under the serum Epo concentration-
time curves (AUC0 _ 48 h) of all patients varied from 20219
to 37926 mU/h per ml (mean 28081.7) and were unrelated
to kidney function.
Pooling the data from all subjects, the apparent volume
of distribution of the injected hormone averaged 0.070 I/kg
(range 0.041-0.099), this corresponds to 1.5 times of the
x K End-stage renal failure
•- — m Moderate renal failure
D — a Normal renal function
6 32 40 4816 24
Hours
Fig. 2. Mean serum concentrations of rHuEpo after a single intravenous
administration of 150 U/kg bodyweight to patients with various degrees
of renal function.
plasma volume. The mean half-life of the distribution
phase (t1/2o) was 1.93 h and did not correlate to kidney
function.
The average total body clearance of rHuEpo in the
whole study group was 0.0913 ml/min per kg (range
0.0613-0.1203) and did not show any correlation with the
creatinine clearance. No significant difference between the
groups could be detected for renal clearance of rHuEpo,
which was found to be less than 3% of total body clearance
(mean 1.86% of total clearance).
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Discussion
The majority of previous studies on the pharmacokinetic
profile of erythropoietin has been carried out with impure
preparations using insensitive and highly variable bio-
assays for the determination of plasma disappearance of
erythropoietin in different animal species and in humans
[9-12]. In recent years the development of sensitive
radioimmunoassays for erythropoietin has provided an
important tool for studies on the pharmacokinetic behav-
iour of the hormone [7]. Our results confirm previous
investigations [5,9-11,13,14], that erythropoietin adminis-
tered by pulse injection is cleared from circulation in a
multiexponential fashion. After exclusion of the initial
distribution phase of the disappearance curve an approxi-
mate monoexponential decay curve of rHuEpo was
obtained. The serum half-life of the injected hormone
averaged 9.03 h and was unffected by renal function. Cor-
responding data were reported in normal healthy volun-
teers [6] and in patients on maintenance haemodialysis
[4,5]. In these studies mean half-life of rHuEpo after the
first injection ranged between 8.6 h and 12 h and was unre-
lated to the dose of the hormone. A significant decrease in
half-life could be observed on continued treatment with
rHuEpo [4,5]. Animal data with 35S-labelled and biologi-
cally active recombinant erythropoietin did not show any
difference in the half-life of the hormone in normal and
uraemic rats with 12.8 h and 11.5 h respectively. However,
in a pharmacokinetic study in the rat with pure human
erythropoietin labelled with 125I, the plasma half-life of
the hormone was significantly prolonged from 3.5 h in
normal rats to 4.4 h in animals with ligated renal pedicles
under steady-state conditions [13]. Similar data were
obtained in dogs by use of 12SI-labelled purified recombi-
nant erythropoietin (rEpo) [14]. The mean elimination
half-life for 125I-rEpo in intact dogs (9.0±0.6h) and
anephric dogs (13.8±1.4h) was significantly different
(P < 0.05). Previous observations together with the results
of the present investigation suggest that peripheral eryth-
ropoietin elimination occurs mainly through non-renal
mechanisms.
In patients with normal and impaired renal function the
apparant volume of distribution of the injected hormone
approximated to 1.5 times the plasma volume. This finding
indicates that rHuEpo penetrates the extracellular space,
even if the distribution volume of the hormone was found
to be smaller than the latter. Confirmation of the substan-
tial extravascular distribution space was also obtained in
different animal species and in humans [6,9-12,13,14]. The
total body clearance values of rHuEpo obtained in this
study were consistently low (0.0613-0.1203 ml/min per kg)
and were not influenced by decreasing renal function. In
contrast, Fu et al. reported a 30% decrease of elimination
clearance of 12SI-rEpo after bilateral nephrectomy when
compared with that of the intact dog. Thus species differ-
ences in the pharmacokinetic profile of erythropoietin
must be considered likely. In comparison with the protein
hormones insulin, glucagon or prolactin [16-18], the
metabolic clearance rate of erythropoietin in rats was
found to be considerably less but was similar to the meta-
bolic clearane rate of glycoprotein hormones as homolo-
gous luteinizing and follicle stimulating hormone{13].
The renal handling of erythropoietin is still unclear.
Although kidney homogenates degraded 125I-Epo in
vitro [13], the physicochemical characteristics of this gly-
coprotein hormone probably impede its degradation and
elimination by the kidneys. In the present study, renal
clearance of rHuEpo accounted for less than 3% of total
body clearance and did not depend on renal function.
These data are in close agreement with previous reports
suggesting that in rats, dogs and humans the urinary ex-
cretion contributes only 4%-10% of the overall elimin-
ation rate of erythropoietin [11-13]. In view of this finding
it seems likely that peripheral erythropoietin disposal
occurs mainly through the liver and possiby through
erythropoietic tissue.
In summary, this study demonstrates, that the peri-
pheral metabolism of rHuEpo is remarkably sluggish and
depends mainly on extrarenal elimination mechanisms.
References
1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Dowing MR, Cotes
PM. Effect of human erythropoietin derived from recombinant
DNA on the anaemia of patients maintained by chronic haemo-
dialysis. Lancet 1986; 2: 1175-1178
2. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW.
Correction of the anemia of end-stage renal disease with recombi-
nant human erythropoietin: results of a Phase I and II clinical trial.
N Engl J Med 1987; 316: 73-78
3. Winearls CG, Cotes PM, Pippard M, Reid C, Oliver DO. Correc-
tion of anaemia in haemodialysis patients with recombinant eryth-
ropoietin - follow up and results of pharmacokinetics, ferrokinetics
and bone marrow culture studies. Xth International Congress of
Nephrology. London 26-32 July 1987, Abstracts, p. 183
4. Muirhead N, Keown PA, Slaugther D et al. Recombinant human
erythropoietin in the anaemia of chronic renal failure: a pharmaco-
kinetic study. Nephrol Dial Transplant 1988; 3:499
5. Egrie JC, Eschbach JW, McGuire T, Adamson JW. Pharmaco-
kinetics of recombinant human erythropoietin (rHuEpo) adminis-
tered to hemodialysis (HD). Kidney Int 1988; 33: 262
6. Urabe A, Tabaku F, Mizoguchi H et al. Effect of recombinant
human erythropoietin on the anemia of chronic renal failure. Int J
Cell Cloning 1988; 6: 179-191
7. Eckardt K-U, Kurtz A, Hirth P, Scigalla P, Wieczorek L. Bauer C.
Evaluation of the stability of human erythropoietin in samples for
radioimmunoassay. Klin Wochenschr 1988; 66: 241-245
8. Committee for pharmacokinetic nomenclature of the American
College of Clinical Pharmacology, Philadelphia, Pennsylvania.
Manual of symbols, equations and definitions in pharmacokinetic. J
Clin Pharmacol 1982; 22: V.
9. Reisman KR, Dietrich DA, Ito K, Schmaus JW. Influence of disap-
pearance rate and distribution space on plasma concentration of
erythropoietin in normal rats. J Clin Invest 1965; 65: 967-975
10. Roh BL, Paulo LG, Thompson J, Fisher JW. Plasma disappearance
of' "I-Iabeled erythropoietin in anesthetized rabbits. Proc Soc Exp
Biol Med 1972; 141:268-270
11. Weintraub AH, Gordon AS, Bucker EL, Camiscoli JF, Contrera
Single-dose Pharmacokinetics of rHuEpo in Varying Degrees of Renal Failure
JF. Plasma and renal clearance of exogenous erythropoietin in the
dog. Am J Physiol 1964; 207: 523-529
12. Rosse WF, Waldmann TA. The metabolism of erythropoietin in 16.
patients with anemia due to deficient erythropoiesis. J Clin Invest
1964:43:1348-1354
13. Emmanouel DS, Goldwasser E, Katz AJ. Metabolism of pure 17.
human erythropoietin in the rat. Am J Physiol 1984; 247: F168-F176
14. Fu J-S. Lertora JJL, Brookins J, Rice JC. Fisher JW. Pharmaco-
kinetics of erythropoietin in intact and anephric dogs. J Lab Clin
Med 1988; 111:669-676 18.
15. Scigalla P, Hoelk G. Pahlke W. Pharmacokinetics of recombinant
349
erythropoietin (rEpo) in normal and uraemic rats. Nephrol Dial
Transplant 1987; 2: 389
Emmanouel DS, Fang VS. Katz J. Prolactin metabolism in the rat:
role of the kidney in degradation of the hormone. (Renal Fluid
Electrolyte Physiol 9) Am J Physiol 1981; 240: F437-F445
Emmanouel DS, Jaspan JB, Rubenstein AH, Huen AH-J, Fink E,
Katz AJ. Glucagon metabolism in the rat. Contribution of the
kidney to the matabolic clearance rate of the hormone. J Clin Invest
1978:62:6-13
Katz AJ, Rubenstein AH. Metabolism of proinsulin, insulin and
C-peptideintherat.yc/in/m«( 1973; 52: 1113-1121
Received for publication 18.1.89
Accepted 24.1.89
